BioPharmSignal logoBioPharmSignal

Biotech News

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesCommercial

Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to

Related news

ADPTAdaptive Biotechnologies2026-05-21 20:18 EST

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

PAVMPAVmed2026-08-04 12:30 EST

Lucid Diagnostics to Participate in Upcoming Investor Conferences

NEPHNephros2026-07-06 11:00 EST

Nephros Announces Inclusion in the Russell Microcap® Index

IARTIntegra LifeSciences2026-06-23 12:00 EST

Integra LifeSciences Announces Key Executive Appointments

CVRXCVRx2026-06-09 11:30 EST

CVRx Announces Chief Financial Officer Transition

PAVMPAVmed2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

XAIRBeyond Air2026-06-01 12:00 EST

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

SSKNStrata Skin Sciences2026-07-28 13:15 EST

STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data

Close
23.60 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States